Roche Wins Genentech, But Will Biotech Employees Remain?
Executive Summary
After eight months of haggling, Roche finally struck a deal to pay $95 a share for Genentech, an iconic biotech in which the drug maker already owns a 56 percent stake
You may also be interested in...
EMA Looks At Avastin, As Novartis/Roche Appeal Italian Competition Fines
With EMA deliberating about Avastin, Novartis and Roche have confirmed that they will appeal the €180.5 million fine imposed on them by Italy’s competition authority for anti-competitive behavior.
Blinding Them With Science: Genentech Tries To Win Shareholders Over
Genentech's March 2 presentation to analysts and investors - a four hour plus love-in dominated by talk of peptides and pathways - seems to have worked
Roche Blinks But Is $93 Enough For Genentech Shareholders?
The $6.50 per share increase in Roche’s offer also includes an extension of the tender deadline to March 20.